# Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

> **NCT06361563** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 250 (actual)

## Conditions studied

- Upper Gastrointestinal Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06361563
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-05
- **Primary completion:** 2024-01-25
- **Final completion:** 2024-01-25
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361563, "Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06361563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*